Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,473,375 papers from all fields of science
Search
Sign In
Create Free Account
Femara
Known as:
Femara®
, Fémara
, Novartis Brand of Letrozole
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
Broader (5)
Antineoplastic Agents
Enzyme Inhibitors
Nitriles
Triazoles
Expand
CGS 20267
letrozole 2.5 MG Oral Tablet [Femara]
letrozole/tamoxifen
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract OT3-02-06: Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial
Q. Khan
,
L. Prochaska
,
+11 authors
P. Sharma
2017
Corpus ID: 57895951
Background: In early ER+ breast cancer, neo-adjuvant (NA) endocrine therapy (ET) may identify a subset of patients with endocrine…
Expand
2016
2016
Abstract PD2-01: Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and…
J. O’Shaughnessy
,
D. Yardley
,
+14 authors
I. Smith
2016
Corpus ID: 77360745
Background The FACE trial was designed to evaluate the efficacy and safety of adjuvant letrozole (LET) versus anastrozole (ANA…
Expand
2016
2016
Abstract P5-12-02: Effect of 5 vs 2.5 mg/day letrozole on residual estrogen levels in post-menopausal women with high BMI - A prospective crossover study
D. Cescon
,
M. Ennis
,
+7 authors
P. Goodwin
2016
Corpus ID: 77252939
Background: Some studies have suggested that women with high BMI have less benefit from aromatase inhibitors (AI) vs. tamoxifen…
Expand
2008
2008
Lapatinib plus letrozole prolongs disease control in subset of patients
C. Helwick
2008
Corpus ID: 182237392
Lapatinib (Tykerb) plus letrozole (Femara) may delay disease progression in metastatic breast cancer patients, according to an…
Expand
Review
2008
Review
2008
San antonio breast cancer symposium.
W. Alexander
P & T : a peer-reviewed journal for formulary…
2008
Corpus ID: 30798356
The use of aromatase inhibitors can increase disease-free survival in postmenopausal women with estrogen receptor– positive (ER…
Expand
2007
2007
Tamoxifène versus inhibiteurs de l'aromatase : quels bénéfices pour quelle tolérance ?
A. Lesur
,
P. Khalifa
2007
Corpus ID: 78149186
FEMARA 2,5 mg comprimé pelliculé (létrozole). FORME,PRÉSENTATION ET COMPOSITION. FORME,PRÉSENTATION ET COMPOSITION :Comprim…
Expand
2006
2006
Letrozole (Femara) causes potent suppression of breast cancer tissue estrogen levels in the neoadjuvant setting.
J. Geisler
,
Hildegunn Helle
,
D. Ekse
,
Nhat K. Duong
,
D. Evans
,
P. Lønning
Journal of Clinical Oncology
2006
Corpus ID: 22781942
10532 Background: Aromatase inhibitors of the third generation like letrozole, anastrozole and exemestane are known to suppress…
Expand
2005
2005
Clinical Trial of Letrozole (femara) versus Aminoglutethimide in Postmenopausal Women with Advanced Breast Cancer
Xiaoqing Liu
,
San‐tai Song
,
Zefei Jiang
,
Wei-lian Li
,
Wei-xia Wang
,
Hui Yang
2005
Corpus ID: 71834341
AbstractObjective: To compare the response and adverse reactions of aminoglutethimide with that of femara, an oral aromatase…
Expand
2003
2003
The place of hormonal therapy in breast cancer treatment with taking into consideration the role of letrozole (Femara
J. Rolski
,
M. Pawlicki
2003
Corpus ID: 78134609
W ci1gu ostatnich lat obserwuje siê wzrost skutecznoœci leczenia hormonalnego stosowanego u chorych na raka sutka. Wynika to z…
Expand
2001
2001
Femara approved as first-line breast cancer therapy.
FDA consumer
2001
Corpus ID: 34766129